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Background. Inflammatory breast cancer (IBC) is a rare but most aggressive breast cancer subtype. The impact of locoregional
therapy on survival in IBC is controversial. Methods. Patients with nonmetastatic IBC between 1988 and 2013 were identified in
the Surveillance, Epidemiology, and End Results (SEER) registry. Results. We identified 7,304 female patients with nonmetastatic
inflammatory breast cancer (IBC) who underwent primary tumor surgery. Most patients underwent total mastectomy with only
409 (5.6%) undergoing a partial mastectomy. In addition, 4,559 (62.4%) were also treated with radiation therapy. The patients who
underwent mastectomy had better survival compared to partial mastectomy (49% versus 43%,𝑝 = 0.003).The addition of radiation
therapy was also associated with improved 5-year survival (55% versus 40%, 𝑝 < 0.001). Multivariate analysis showed that black
race HR (1.22, 95% CI 1.18–1.35), ER negative status (HR 1.22, 95% CI 1.16–1.28), and higher grade (HR 1.14, 95% CI 1.07–1.20)
were associated with poor outcome. Cox proportional hazards model showed that total mastectomy (HR 0.75, 95% CI 0.65–0.85)
and radiation (HR 0.64, 95% CI 0.61–0.69) were associated with improved survival. Conclusions. Optimal locoregional therapy for
women with nonmetastatic IBC continues to be mastectomy and radiation therapy. These data reinforce the prevailing treatment
algorithm for nonmetastatic IBC.
1. Introduction
Inflammatory Breast Cancer (IBC) is an uncommon, aggres-
sive breast cancer subtype that accounts for approximately 2%
of breast cancers diagnosed annually in the United States [1].
IBC is defined by specific clinicopathologic features including
edema (peau d’orange) and erythema of more than one-
third of the skin and often has microscopic evidence of
dermal lymphatic tumor emboli [2]. IBC is associated with a
locoregional recurrence rate of 19.5% [3] and extremely poor
long-term outcomes with a median survival of 2.9–3.8 years
[4, 5].
Historically, treatment of IBC with surgery and/or radio-
therapy alone resulted in five-year survival rates of less than
5% [6]. The use of preoperative chemotherapy has been
associated with significant improvements in overall survival.
Current treatment guidelines for IBC [7, 8] recommend
sequential trimodality therapy consisting of preoperative
anthracycline-based polychemotherapy (including targeted
therapy depending onHER2 receptor status) followed by total
mastectomy with a level I/II axillary node dissection and
postmastectomy radiation. Hormonal therapy is prescribed
as indicated by the status of the estrogen and progesterone
receptors [9].
Locoregional therapy has historically been considered
important for the control of symptomatic chest wall disease
and/or the prevention of locoregional recurrence. Whether
the addition of locoregional therapy to anthracycline-based
chemotherapy impacts survival in IBC remains controversial,
especially the extent of surgery [10]. Several authors [11, 12]
have reported similar survival rates in small cohort studies
with patientswhounderwent breast conserving surgerywhen
compared to patients who underwent total mastectomy after
preoperative systemic therapy and have questioned whether
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N = 11,604 patients with T4d, N0–3, M0 IBC as per 
adjusted AJCC 6th TNM were identified
Excluded autopsy alone or death certificate alone 
cases.
N = 7304 patients with non-metastatic inflammatory 
breast cancer with documented primary site surgery
Excluded patients with missing 
or no primary site surgery 
n = 4300 excluded patients with
missing or no primary site surgery
Figure 1
IBC is an absolute contraindication to breast conservation
therapy. However, these reports are from single institutions
and have a small sample size. The purpose of this study is to
examine the impact of locoregional therapy, particularly the
extent of surgical therapy, on survival in a large population
cohort of women with nonmetastatic IBC.
2. Materials and Methods
2.1. Patient Population. Weobtained data fromNational Can-
cer Institute’s Surveillance, Epidemiology, and End Results
(SEER) registries. SEER currently collects and publishes
cancer incidence and survival data from population-based
cancer registries that cover approximately 28 percent of the
US population. A query of the SEER registry using SEER∗Stat
8.1.2 was performed to identify patients with nonmetastatic
IBCdiagnosed between the years January 1988 andDecember
2013. The search was restricted to females with Adjusted
AJCC 6 Stage III (T4d, N0–3, M0) IBC. IBC was also defined
according to the AJCC sixth edition and was categorized
and coded within the SEER registry database as T4d disease.
According to the AJCC sixth edition, IBC is defined as being
characterized by diffuse erythema and edema (peau d’orange)
of the breast, frequently without an underlying palpable
mass. We collected demographic data (age at diagnosis, race)
and tumor characteristics (stage, histologic subtype, estrogen
(ER) and progesterone (PR) receptor expression status, and
HER2 overexpression status). For selection of cases, see
Figure 1.
Patients with Procedure Codes 20–24 were considered to
have had a partial mastectomy, while patients with Procedure
Codes 30–80 were considered to have had a mastectomy.
Patients with Procedures Codes 00 (no surgery performed),
90 (surgery, NOS), or 99 (unknown if surgery was per-
formed) were excluded from the analysis.
Patients with the estrogen receptor (ER) status or proges-
terone receptor (PR) status being borderline were considered
positive as per the SEER breast cancer subtype algorithm.
Patients with HER2 status reported as either borderline or
unknown were not utilized to characterize the breast cancer
subtype. SEER began collectingHER2 receptor status data for
breast cancer cases in 2010. For this study we divided patients
into three subtypes. The hormone receptor positive subtype
was defined as estrogen receptor and or progesterone receptor
positive andHER2negative,HER2ositive subtype as estrogen
and or progesterone receptor positive or negative with HER2
positive, and triple negative subtypes as estrogen receptor,
progesterone receptor, and HER2 negative.
2.2. Statistical Analysis. Univariate comparison between
groups was performed by means of the Student 𝑡-test or chi
square test where appropriate. Survival was defined as time
from date of diagnosis to date of last contact or date of death.
Survival was calculated utilizing the method of Kaplan-
Meier and significant differences were determined by the log
rank test. The Cox proportional hazards regression model
was used to determine hazard ratios for overall (OS) and
disease specific survival (DSS). All statistical analyses were
performed utilizing NCC Statistical Software (version 10,
Kaysville, Utah).
3. Results
During the study time, 11,604 women were diagnosed with
nonmetastatic IBC. Of these women, 7,304 patients had
locoregional treatments documented and formed the basis
of this analysis. The majority (6,895 patients) underwent
total mastectomy while only 409 (5.6%) underwent partial
mastectomy. Of patients who underwent a defined surgical
procedure, 4,559 (62.4%) were also treated with radiation
therapy.
Table 1 summarizes the characteristics of the study popu-
lation.Women who underwent total mastectomy when com-
pared with those who underwent partial mastectomy were
on average slightly older (mean age at diagnosis 60.1 versus
57.1, 𝑝 < 0.001). Nonwhites comprised a greater percentage
of women who underwent partial mastectomy (𝑝 < 0.001).
The partial mastectomy and total mastectomy subgroups
had similar rates of ER receptor positivity (𝑝 = 0.02),
PR receptor positivity (𝑝 = 0.14), and histologic subtype
(𝑝 = 0.36).
The patients with lower nodal burden, later years of
diagnosis, and mastectomy were associated with better out-
come (Table 2). Triple negative breast cancer was associated
with inferior DSS (HR: 2.40, 95% CI 1.76–3.51), and HER 2-
positive group was associated with superior DSS (HR: 0.66,
95% CI 0.44–0.98) but this group had smaller sample size.











































Figure 2: Kaplan-Meier survival curves for patients stratified by type of surgery ((a),𝑝 = 0.003) and treatment with radiation ((b),𝑝 < 0.001).
Table 1: Study population characteristics.
Variable Total Partial mastectomy Total mastectomy 𝑝 value
Number of patients 7304 409 6895
Age (yrs)
Mean 56 60.1 57.1 <0.001
Range 21–103 25–97 21–103
Race (%) <0.001
White 5871 (80.4) 309 (75.6) 5562 (80.7)
Black 1003 (13.7) 81 (19.8) 992 (13.4)
Other 430 (5.9) 19 (4.6) 411 (5.9)
N stage <0.001
N0 1147 (15.7) 147 (35.9) 1000 (14.5)
N1 2478 (33.9) 143 (35.0) 2335 (33.9)
N2 1788 (24.5) 66 (16.1) 1722 (25.0)
N3 1891 (25.9) 53 (13.0) 1838 (26.6)
ER status 0.02
Positive 3458 (47.3) 189 (46.2) 3269 (47.4)
Negative 3147 (43.1) 165 (40.3) 2982 (43.3)
Unknown 699 (9.6) 55 (13.5) 644 (9.3)
PR 𝑆𝑡𝑎𝑡𝑢𝑠 0.14
Positive 2671 (36.6) 151 (36.9) 2520 (36.6)
Negative 3870 (53.0) 204 (49.9) 3666 (53.2)
Unknown 709 (10.4) 54 (13.2) 763 (10.34)
Subtype 0.36
HR + 579 (38.4) 29 (42.0) 550 (38.2)
HER2 + 535 (35.5) 19 (27.5) 535 (35.8)
Triple negative 374 (26.1) 21 (30.5) 395 (25.0)
Age ≥ 50, black race, greater nodal disease burden, ER-
negative tumors, PR-negative tumors, and treatment prior
to 2000 were associated with inferior outcome (Table 2).
Patients who had a mastectomy had a 5-year survival of 49%
(median survival 59mos) compared to a 5-year survival of
43% (median survival 47mos) in women who had a partial
mastectomy (𝑝 = 0.003) (Figure 2(a)). The addition of
radiation therapy was significantly associated with improved
overall survival (5-year survival 55% versus 40%, 𝑝 <
0.001) (Figure 2(b)). By multivariate analysis using the Cox
proportional hazardsmodel, total mastectomy (HR 0.75, 95%
CI 0.65–0.85) and the delivery of radiation (HR 0.64, 95% CI
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Table 2: Cox proportional hazards model for overall survival and disease specific survival.
Variable Overall survival Disease specific survival
𝑝 Value HR 95% CI 𝑝 Value HR 95% CI
Node status <0.001 <0.001
N0 Referent Referent
N1 1.26 1.13–1.39 1.50 1.31–1.73
N2 1.65 1.47–1.83 2.01 1.74–2.31
N3 2.28 2.05–2.53 2.90 2.50–3.30
Year Dx <0.001 <0.001
1988–1999 Referent Referent
2000–2013 0.81 0.75–0.86 0.77 0.70–0.83
Surgery <0.001 0.004
PM Referent Referent
TM 0.75 0.66–0.86 0.79 0.67–0.92
Race <0.001 <0.001
White Referent Referent
Black 1.49 1.37–1.63 1.60 1.43–1.75
Other 0.84 0.73–0.97 0.84 0.70–0.98
Radiation <0.001 <0.001
No Referent Referent
Yes 0.64 0.60–0.69 0.7 0.65–0.80
ER status <0.001 <0.001
Positive Referent Referent
Negative 1.38 1.26–1.50 1.40 1.30–1.60
Unknown 1.49 1.15–1.93 1.63 1.21–2.20
PR status <0.001 <0.001
Positive Referent Referent
Negative 1.22 1.11–1.34 1.35 1.22–1.51
Unknown 0.96 0.75–1.25 0.97 0.72–1.30
Age (yrs) <0.001 <0.001
<50 Referent
≥50 1.28 1.19–1.37
0.60–0.68) remained significantly associated with improved
survival.
4. Discussion
Despite substantial improvements in the outcomes of women
with IBC over the last several decades, the majority of
patients develop and subsequently succumb to metastatic
disease [2]. In view of the grave prognosis of IBC, some have
questioned whether routine treatment with total mastectomy
and level I/II axillary node dissection is necessary for a better
outcome given the systemic nature of the disease. In this
population-based study of women with nonmetastatic IBC,
we sought to examine the impact of locoregional therapy on
survival.Our results indicate that totalmastectomy compared
with partial mastectomy is associated with improved overall
and disease specific survival, and the addition of radiation
therapy significantly improves overall survival. Although the
partial mastectomy and total mastectomy subgroups had sev-
eral significant demographic differences, partial mastectomy
remained independently associated with poorer survival in
a Cox regression model. It is possible that the extent of
axillary surgery is a confounding variable despite the use of
multivariate analysis.Themastectomy subgroup had a greater
burden of nodal disease and it has been demonstrated that
aggressive locoregional therapy may be more beneficial in
patients with high tumor burden [13]. On the other hand,
women in the partialmastectomy subgroupwere significantly
older and more likely to be nonwhite, characteristics fre-
quently associated with worse outcomes [1]. Another possible
explanation for poorer outcomes with partial mastectomy
is the self-seeding hypothesis, the observation that primary
tumors may seed distant sites as well as reseed the primary
tumor site [14].
The optimal extent of surgery in IBC is unclear and since
earlier studies opted for mastectomy which demonstrated
improved survival, mastectomy became an integral part of
trimodality therapy in IBC. Recently breast conservation
surgery has generated interest due to modernization of
both imaging and systemic therapeutic options. Our finding
that partial mastectomy is associated with poorer survival
contrasts with two small reports on breast conservation
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therapy in women with IBC. Bonev and colleagues [11]
retrospectively analyzed a series of 24 patients with IBC
and found no significant difference in overall survival at
median follow-up of 60 months between women who under-
went partial mastectomy versus total mastectomy following
neoadjuvant chemotherapy (overall survival 59% versus 57%,
0.49). Similarly, in a retrospective single-institution analysis,
Brzezinska and colleagues [12] found that 35womenwith IBC
treated with breast conservation surgery had similar rates
of locoregional control and survival compared with those
treated with mastectomy. The contrast between our finding
and the conclusions of these two reports could be explained
by differences in patient populations, tumor biology, and
variations in treatment regimens. For example, nearly half of
the patients in the UK study [12] were treated with neoadju-
vant endocrine therapy rather than chemotherapy suggesting
predominance of favorable breast subtype in this cohort.
In noninflammatory breast cancer, survival following breast
conservation therapy has repeatedly been demonstrated to
be equivalent to that following mastectomy. The rationale
for these trials stemmed from the hypothesis that breast
cancer is a systemic disease [15]. Our observation that partial
mastectomy is associated with poorer survival for patients
may also point towards that IBC is a heterogeneous group
of tumors with variable clinical course [16]. Although partial
mastectomy was associated with poorer survival in this large,
unselected patient population, it is possible that there are
subsets of women with IBC for whom breast conservation
therapy may be an acceptable alternative to modified radical
mastectomy especially for patients with complete clinical and
imaging response to preoperative systemic therapy [3].
Genomic profiling, functional imaging, and character-
ization of additional tumor markers like EXH2 expression
[17, 18] may facilitate the identification of tumors for which
breast conservationmay achieve optimal locoregional control
and disease-free survival in future.
Our data also demonstrates that the inclusion of radiation
therapy in the multimodal treatment of nonmetastatic IBC
impacts survival favorably. This data should be interpreted
with caution as SEER does not capture the dose and site
specific details of radiation therapy delivered. This is concor-
dant with extant data on noninflammatory breast cancer [19].
Response guided treatment may improve patient selection
for more aggressive locoregional treatment in IBC. Patients
with suboptimal or nonresponsive disease to preoperative
systemic therapy may benefit from preoperative radiation
with or without concurrent chemotherapy with some reports
in locally advanced breast cancer demonstrating improved
response rates and local control [20].
Our data has several limitations inherent to population-
based studies. These include missing data as well as lack of
treatment details about the systemic therapy, the sequencing
of therapies, radiation dosage, and fields of treatment. SEER
database does not provide information about the scope of
regional lymph node surgery and surgical margin status.
While a prospective, randomized controlled trial would
be ideal to assess the impact of locoregional therapies on
survival, this is a challenge given the rarity and lethality of
IBC.
5. Conclusions
This study demonstrates that optimal locoregional therapy
for women with nonmetastatic IBC consists of both total
mastectomy and radiation, not only for control of chest wall
disease but also for survival. Further studies are needed to
determine whether there may be specific subsets of patients
for whom breast conservation therapy may be a reasonable
alternative to total mastectomy.
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